Cystic Fibrosis Therapy Device Uses Voice Coil Technology to Improve Mobility
In this episode of MedDevice by Design, Mark Drlik and Ariana Wilson share the story behind a novel cystic fibrosis therapy device that transformed a cumbersome hospital-grade system into a lightweight, wearable solution. The innovation journey begins with a prototype and ends with the Hillrom Monarch system—a commercially available device that enhances patient quality of life.
From Pneumatics to Portability
Traditional chest wall oscillation therapy for cystic fibrosis patients involves large pneumatic generators and bulky vests. While effective, these systems are noisy and restrict movement, making them challenging for home use. To address this, Mark and his team developed a new solution based on voice coil technology—a compact, precise, and quiet alternative.
Instead of relying on air-driven percussion, the redesigned device uses voice coils to deliver targeted chest wall oscillation. Patients can move freely while receiving therapy, improving both comfort and adherence.
How It Started: Prototype to Product
The project began when innovator Martin DeVlieger brought an early concept to StarFish Medical. The team refined the idea through engineering design, prototyping, and collaboration. Eventually, the technology was acquired by Hillrom and became the Monarch Airway Clearance System—now making a real impact in the lives of people with cystic fibrosis.
Why This Matters for MedTech
This episode highlights the importance of user-centered design in creating therapy devices that truly meet patient needs. It also underscores the value of strategic partnerships in bringing groundbreaking innovations to market.
Whether you’re an engineer, entrepreneur, or caregiver, this story offers insight into the development of cystic fibrosis therapy devices that combine technical performance with everyday usability.
Enjoying MedDevice by Design? Sign up to get new episodes sent to your inbox.
Related Resources
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.
Nigel Syrotuck breaks down the realistic medical device V&V cost and schedule for terminally sterilized devices, picking up after design freeze and walking through each major phase of the process.
Nigel Syrotuck examines the hidden medical device sterilization costs that many development teams overlook when estimating the true cost of producing a terminally sterilized device.